Twitxy Saved

Daniel Bryan Goodman

@dbgoodman

Immuno/Synth Bio/ML. PI @PennMedicine/@parkerici. Using DNA synth, multiplex assays & generative models to understand & engineer immune cells. @geochurch alum.
Harvard/MIT ➡️ UCSF ➡️ UPenn goodman-lab.org Joined May 2009
2.2K Following 2.3K Followers 2.5K Posts

Latest posts 5

Daniel Bryan Goodman @dbgoodman
👇👇👇👇👇👇
Jake Wintermute 🧬/acc Verified account @SynBio1 Oct 7
In the AI era, I expect to see many new modalities emerge in biotech. These will be therapeutics in unusual shapes and sizes, not the legacy small molecule drugs that our IP laws, tech transfer departments and biopharma term sheets were designed to bring to market.

CRISPR was a practice run. It was an experiment to see how well the existing biotech ecosystem is set up to commercialize new modalities. 14 years after the CRISPR patent wars, it should be seen as a failure and motivate significant reform.

Imo the failure of CRISPR reveals two needs:

1) We need better legal and financial tools for nonexclusive foundational IP licenses. If a new modality has 100 applications, we can't assign exclusive rights to 3 companies who then spend the next decade suing each other.

2) We need better infrastructure for modality-wide safety trials and re-use of clinical data. If a new modality has 100 applications, we shouldn't demand that each use build a new portfolio of clinical evidence from scratch.

I believe the AI era will deliver dozens of CRISPR-scale new medical innovations. Let's not allow the CRISPR fiasco to happen again.

statnews.com/2026/10/07/car…
View quoted post on X
Daniel Bryan Goodman @dbgoodman
This is a good rebuttal to the virtual cell haters, but it's not what is in the pitch decks...
Patrick Hsu Verified account @pdhsu Dec 17, 2025
my view is we need to start somewhere and add complexity over time. many structural biologists complained about alphafold, eg how it doesn’t mechanistically model the biophysics of protein folding or disordered/dynamic regions. so is protein folding definitively solved? well, alphafold is sufficiently accurate that it’s undeniably useful and important, and has accelerated or replaced many wet lab experiments and helped people beyond the specific domain of structural biology. in the early days of CASP no one agreed on metrics. but the structure prediction field has matured into commonly accepted metrics that are used across papers

we have started with perturbation prediction because such a model can pragmatically guide wet lab experiments and target ID is such a useful capability. I don’t think it’s controversial that accurate perturbation prediction will be hugely impactful across many fields of basic science and therapeutics.

and sure, we want to eventually model temporal dynamics, metabolite gradients, cellular interactions, etc. that’s why we created VCC as a community effort that will grow over time with tailored datasets and evals across these dimensions
View quoted post on X
1 replies 0 reposts 5 likes 6.6K views View on X
Daniel Bryan Goodman @dbgoodman
Very impressed with the work of @NornGroup and @impetusgrants so far, and their thoughtful and bold approach to funding & accelerating longevity research.
Martin Borch Jensen Verified account @MartinBJensen Sep 2, 2025
Is the longevity field making progress?
@NornGroup formed in 2021 to address that question. We’ve now built a website to make it clear who we are and how we work to make longevity medicine real. Read on for a summary, and some of our outputs.
View quoted post on X